White Paper

How Much Can You Learn From Limited Drug Substance?

GettyImages-2183237842-glp-1-peptide-red-light-blue-code

Formulation, analytical, and process development draw on the same finite supply of drug substance. For complex or high-value APIs, that supply can run short well before the questions do. Teams need enough data to make sound decisions, yet each study consumes material that may be hard to replace.

The answer is not simply to use less. It involves deciding which questions call for manufacturing-scale experiments, which can be answered at a fraction of the volume, and where active product is indispensable. It also means looking at where material can be lost during manufacturing, since small losses matter more when drug substance is scarce.

This white paper draws on hands-on development experience at a sterile drug product facility in Monza, Italy, and includes a worked example from a peptide-based drug product, with material figures attached. The perspective is practical and specific to sterile development.

Read the white paper below to see how material-efficient development works in practice.

Access The White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma